Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Dose-escalating Phase Ia Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLF31907 Injection in Patients With Advanced Cancer

Next Previous
X
Search
Trial Profile

An Open, Dose-escalating Phase Ia Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLF31907 Injection in Patients With Advanced Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QLF 31907 (Primary)
  • Indications B-cell lymphoma; Carcinoma; Cervical cancer; Diffuse large B cell lymphoma; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Peripheral T-cell lymphoma; Renal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Qilu Pharmaceutical

    • Most Recent Events

    • 06 Jun 2024 Results published in the Qilu Pharmaceutical Media Release
    • 06 Jun 2024 According to a Qilu Pharmaceutical media release, data from this trial presented at The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    • 04 Jun 2024 Results (As of 30 Nov 2023, n=38 pts) presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top